Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2010 Financial Results
Date:11/4/2010

NEW YORK, Nov. 4, 2010 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease (the "Company"), today announced its results for the third quarter ended September 30, 2010.

At September 30, 2010, the Company had cash, cash equivalents, interest receivable and investment securities of $34.4 million, as compared to $31.7 million at June 30, 2010, and $35.9 million at December 31, 2009.  During the third quarter, the Company received approximately $5.7 million in net proceeds from the exercise of the remaining warrants from the Company's September 2009 registered direct offering.

The net loss for the third quarter ended September 30, 2010 was $5.8 million, or $0.10 per diluted share, compared to net income of $0.6 million, or $0.01 per diluted share, for the third quarter in 2009, representing a change in net (loss) income of $6.4 million.  The three months ended September 30, 2009 included $3.5 million in other revenue, related to the settlement of a dispute with the former licensor of Sulonex (sulodexide), in July 2009, over issues arising from the terminated license agreement.  The three months ended September 30, 2010 included a $2.2 million increase in research and development expenses related to KRX-0401 (perifosine) and Zerenex as compared to the comparable period last year, primarily related to the Company's ongoing Phase 3 clinical development programs.  The net loss for the third quarter ended September 30, 2010, included $0.6 million of non-cash compensation expense related to equity incentive grants.

The net loss for the nine months ended September 30, 2010 was $15.0 million, or $0.26 per diluted share
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Aug. 4, 2015 BioElectronics Corporation (OTC ... Musculoskeletal Pain Therapy medical devices, announced today that ... ActiPatch 7-day trial device has been published in ... Management http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  More than 5,000 ... submitted an assessment.  Chronic pain ...
(Date:8/4/2015)... Research and Markets ... Jain PharmaBiotech,s new report "Animal Biotechnology - ... This report describes and evaluates animal ... pharmaceuticals as well as improvement in food production. ... application of biotechnology to manage genetic disorders and ...
(Date:8/4/2015)... Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX ),  a targeted oncology ... be presenting at the 2015 Wedbush PacGrow Healthcare Conference on ... PT) in New York . Charles ... will provide a corporate overview. A live audio ... page of Mirati,s corporate website at www.mirati.com . A ...
Breaking Medicine Technology:BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2Animal Biotechnology 2014-2024 - 2015 Technologies, Markets and Companies Analysis 2Animal Biotechnology 2014-2024 - 2015 Technologies, Markets and Companies Analysis 3Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference 2Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference 3
... SPRING, Md., April 28, 2011 The U.S. ... acetate) in combination with prednisone (a steroid) to ... who have received prior docetaxel (chemotherapy). ... cancer, the male sex hormone testosterone stimulates prostate ...
... Sciences Inc. (PSI), a leading pharmaceutical CRO, and ... ethylene vinyl acetate (EVA) into pharmaceutical applications, are ... devices.  Building on years of collaboration, Particle Sciences ... provide Particle Sciences with preferred access to VitalDose™ ...
Cached Medicine Technology:FDA Approves Zytiga for Late-Stage Prostate Cancer 2FDA Approves Zytiga for Late-Stage Prostate Cancer 3Particle Sciences and Celanese EVA Performance Polymers Collaborate to Accelerate Drug-Eluting Device Combinations 2Particle Sciences and Celanese EVA Performance Polymers Collaborate to Accelerate Drug-Eluting Device Combinations 3
(Date:8/4/2015)... ... August 04, 2015 , ... PerceptiMed, ... Richard Carmona, M.D., M.P.H., FACS, to its Board of Directors effective August 1, ... lives," Dr. Carmona said. "I strongly believe in the mission of the company ...
(Date:8/4/2015)... ... August 04, 2015 , ... Seedstock’s ... for Nov. 3 – 4, 2015, at UC San Diego, will explore innovations ... improve food access, and manage resources efficiently against the dueling backdrop of a ...
(Date:8/4/2015)... Mount Horeb, WI (PRWEB) , ... August 04, 2015 , ... ... newly released video on the subject, Renew Man™ is standing up as a voice ... a 15-year veteran of the healthy aging industry with special experience and expertise in ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... They say ... better understand certain health conditions, pictures and medical art can be essential. StayWell, a ... providers. , Krames Patient Education solutions have been used by physicians and other ...
(Date:8/4/2015)... ... August 04, 2015 , ... Discovia, ... entities, today announced that John Munro, a 15-year veteran of the eDiscovery services ... Services Operations. , “I am thrilled to join Discovia at this important point ...
Breaking Medicine News(10 mins):Health News:Dr. Richard Carmona, 17th Surgeon General of the United States, Joins PerceptiMed, Inc.’s Board of Directors 2Health News:Dr. Richard Carmona, 17th Surgeon General of the United States, Joins PerceptiMed, Inc.’s Board of Directors 3Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 2Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 3Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 2Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 3Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 2Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 3Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 2Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 3
... U.S. News & World Report has ranked,Cincinnati Children,s ... United States in general pediatrics in the 2008 edition ... is,the highest Cincinnati Children,s has ever received from U.S. ... we owe a great debt of thanks,to the thousands ...
... WASHINGTON, May 30 The National Alliance on,Mental ... for her,contributions to public education about mental illness ... 2008., NAMI executive director Mike Fitzpatrick made ... in which he discussed the premiere of,two ...
... May 30 The following is being issued,by the Federation ... physician scientists from 58 countries across the globe, What: ... When: Wednesday, June 4-Monday, June 9, Where: Boston Marriott ... accelerate science that improves patient care, Wednesday, June 4, ...
... is Dec. 31, but FDA urges asthma patients to ... (HealthDay News) -- Asthma inhalers that contain the drug ... harm the ozone layer. And these inhalers won,t be ... urging patients to switch to alternative inhalers now. , ...
... hardest hit ... areas of the country, WILMINGTON, ... homeless after Cyclone Nargis swept through Myanmar. Malteser,International has been providing ... of Labutta in the Irrawaddy Delta. Present in,Myanmar since 2001, Malteser ...
... Indiana experienced a 50 percent membership ... growth since 2007, ... this 14-year-old, not-for-profit,Indiana managed health care plan -- surpassing the 300,000 mark ... 2007, the,company has also grown its employee base by 182 percent -- ...
Cached Medicine News:Health News:U.S. News Ranks Cincinnati Children's Among Top Three U.S. Children's Hospitals 2Health News:U.S. News Ranks Cincinnati Children's Among Top Three U.S. Children's Hospitals 3Health News:NAMI Blog: PBS, MTV and Jane Pauley 2Health News:World-Renowned Scientists to Lead Immunology Course 2Health News:World-Renowned Scientists to Lead Immunology Course 3Health News:World-Renowned Scientists to Lead Immunology Course 4Health News:Ozone-Depleting Inhalers Being Phased Out 2Health News:Ozone-Depleting Inhalers Being Phased Out 3Health News:More Than 78,000 are Dead and Millions are Homeless After Cyclone Nargis Swept Through Myanmar 2Health News:MDwise Enrollment Exceeds 300,000 Members 2
...
ENDOlap™ suction and irrigation trumpet valves...
... Clinicians are demanding smaller, higher ... their clinical and operational challenges. The ... a powerful architecture for superb High ... mobility and ease-of-use; and a versatile ...
... The Dimension Vista 1500 integrated ... nephelometry, IMT (integrated multisensor technology) ... design will integrate analysis of ... drugs-of-abuse, therapeutic drugs, immunosuppressive drugs, ...
Medicine Products: